For research use only. Not for therapeutic Use.
Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H+, K+-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H+, K+-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease[1][2].
| Catalog Number | R010253 |
| CAS Number | 131926-99-3 |
| Synonyms | 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfonyl]-1H-benzimidazole |
| Molecular Formula | C16H14F3N3O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C16H14F3N3O3S/c1-10-13(20-7-6-14(10)25-9-16(17,18)19)8-26(23,24)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) |
| InChIKey | TVMJMCGRSSSSDJ-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CN=C1CS(=O)(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F |
| Reference | [1]. Swamy G, et al. Crystal structure of lansoprazole sulfone[J]. Journal of Structural Chemistry, 2007, 48: 715-718. [2]. Karol MD, et al. Lansoprazole pharmacokinetics in subjects with various degrees of kidney function. Clin Pharmacol Ther. 1997 Apr;61(4):450-8. |
